Lhasa Limited shared knowledge shared progress
Loading...
PublicationsJump to results
Authors
Publication Type
Publication Year
Related Products
Reset
New search
TitlePublishedTypeProducts
How To - Filtering Mass DefectDecember 2014Meteor Nexus
How to Become a New Member of Lhasa.pdfFebruary 2015pdf file
How to discover new structural alerts and recognise new secondary molecular attributes that modulate alert effectivenessOctober 2016pdf fileDerek Nexus
How Zeneth fits into ICH Q3DJune 2018pdf fileZeneth
ICH M7 - Have you got it covered?March 2015Derek NexusMirabilisSarah NexusVitic NexusZeneth
ICH M7 - Worked Examples using the new Nexus workflowMarch 2016pdf fileDerek NexusSarah Nexus
ICH M7 BrochureMarch 2018pdf fileDerek NexusSarah NexusVitic NexusZeneth
ICH M7 Classification and the involvement of (Q)SAR methodsOctober 2016pdf fileDerek NexusSarah Nexus
ICH M7 Classification WorkflowMarch 2017pdf fileDerek NexusSarah Nexus
ICH M7 Expert Review ExamplesMay 2019pdf file
ICH M7 Expert Review Workshop - ICH M7 India RoadshowsNovember 2018pdf file
ICH M7 How Lhasa can support you.pdfMarch 2014pdf fileDerek Nexus
ICH M7 Knowledge and Data Sources ManagementMay 2019pdf file
ICH M7 Overview: Predicting, Assessing, and Controlling Mutagenic Impurities from DegradationJune 2018pdf file
ICH M7 Perception WebinarJune 2019MirabilisSetaria
ICH M7 Perception: Unifying Knowledge from Predictions to PurgingMarch 2019pdf fileMirabilisSetariaDerek NexusSarah NexusVitic Nexus
ICH M7 Use CasesJune 2018pdf fileDerek NexusSarah Nexus
ICH M7 Workflow.pdfNovember 2015pdf fileDerek NexusSarah NexusVitic Nexus
ICH M7: An Industry Perspective - ICH M7 India RoadshowsNovember 2018pdf file
ICH Q3D: Practical implementation and the role of excipient data in a risk based approachDecember 2016
ICH Quality Guidelines: An Implementation GuideOctober 2017
ICHQ3D Implementation: Use of published data driven risk assessmentsJune 2019pdf fileVitic Nexus
Identification of Adverse Outcome Pathways for the Nephrotoxicity of Nucleoside and Nucleotide Anti-Viral DrugsMarch 2014pdf fileDerek Nexus
Impact from the Recent Issuance of ANVISA Resolution RDC-53/2015 on Pharmaceutical Small Molecule Forced Degradation Study RequirementsMay 2016Zeneth
Implementation of ICH M7 Recommended (Q)SAR AnalysesMarch 2016pdf fileDerek NexusSarah NexusVitic NexusZeneth

© 2019 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.